Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially the 3rd-generation EGFR-TKIs have demonstrated strong antitumor effects in EGFR-positive patients.
However, approximately 20% of EGFR-positive were primarily resistant to 3rd generation EGFR-TKIs, i.e., clinical non-response or disease progression in the short term.
This study aimed to clarify the molecular indicators that predict the benefits of 3-rd EGFR-TKIs as first-line therapy in NSCLCpatients with EGFR-positive. Further, to clarify their primary drug resistance mechanisms, which is of great significance for the treatment and clinical decision-making of NSCLC disease.
Age >18 years;
Histological or cytopathological diagnosed NSCLC;
According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is unresectable IIIB-IV or recurrence and metastasis after surgery;
At least one measurable lesion can be evaluated according to the Response Evaluation Criteria In Solid Tumours v1.1 (RECIST1.1) criteria;
Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form;
Pregnant and lactating women;
Other malignant neoplastic diseases within 3 years;
Patients who have undergone other clinical drug trials;
Second Xiangya Hospital of Central South University
Lead sponsor
Xiangya Hospital of Central South University
Collaborator
Shanghai Chest Hospital
Collaborator
West China Hospital
Collaborator
Hunan Cancer Hospital
Collaborator
The Third Xiangya Hospital of Central South University
Collaborator
The First Affiliated Hospital of Xiamen University
Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborator
China-Japan Friendship Hospital
Collaborator
Fudan University
Collaborator
First Affiliated Hospital of Kunming Medical University
Collaborator
Loudi Central Hospital
Collaborator
ZhuZhou Central Hospital
Collaborator
Xiangtan Central Hospital
Collaborator
First People's Hospital of Chenzhou
Collaborator
Yueyang Central Hospital
Collaborator
Yongzhou Central Hospital
Collaborator
The First Affiliated Hospital of University of South China
Collaborator
Hunan Provincial People's Hospital
Collaborator
Shaoyang Central Hospital
Collaborator
Yiyang Central Hospital
Collaborator
Changsha Central Hospital
Collaborator
The First People's Hospital of Guiyang
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Renmin Hospital of Wuhan University
Collaborator
The First People's Hospital of Changde City
Collaborator
Zhuzhou Second Hospital
Collaborator
First Hospital of Changsha
Collaborator
Hengyang Central Hospital
Collaborator
Huaihua first people's Hospital
Collaborator
The First People's Hospital of Xiangtan
Collaborator
University of South China Affiliated Nanhua Hospital
Collaborator
Xiangxi Autonomous Prefecture People's Hospital
Collaborator
People's Hospital of Zhangjiajie
Collaborator
Second People's Hospital Of Huaihua
Collaborator
Hunan Academy of Traditional Chinese Medicine Affiliated Hospital
Collaborator
The Third Hospital of Changsha
Collaborator
Xiangya Changde Hospital
Collaborator
Changsha County first People's Hospital
Collaborator
Hunan Provincial Straight Hospital of Traditional Chinese Medicine
Collaborator
Liuyang Hospital of traditional Chinese Medicine
Collaborator
Second People's Hospital of Hunan
Collaborator
First Affiliated Hospital of Guangxi Medical University
Collaborator
Guiyang Public Health Treatment Center
Collaborator
The Affiliated Bethune Hospital of Shanxi Medical University
Collaborator
Hunan University of Traditional Chinese Medicine
Collaborator
Tongji Hospital
Collaborator
The First Affiliated Hospital of Nanchang University
Collaborator